Alnylam Grants IP License to Tekmira for Ebola Drug

Under the deal, Alnylam stands to receive royalties on sales of products developed using the licensed technology. Additional terms were not disclosed.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories